Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin and Fenofibrate in Type 2 Diabetes
NCT00362765Phase 3Terminated
- Sponsor
- Solvay
- Start
- Oct 2006
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of fenofibrate in type 2 diabetes mellitus (T2DM) and dyslipidemia (4 arms), sponsored by Solvay. Primary endpoints: Endogenous Glucose Production at 16 weeks and Glucose Disposal Rate at 16 weeks. Started Oct 2006; status: terminated.
02
Drugs
fenofibrate
03
Conditions
type 2 diabetes mellitus (T2DM)dyslipidemia
Beyond the preview
Go deeper on NCT00362765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00362765.